CJC 1295 with DAC (5mg)

$89.99

Availability: 10 in stock

CJC 1295 with DAC is a synthetic growth hormone-releasing hormone analog studied for its extended half-life, peptide signaling activity, and sustained growth hormone modulation pathways. Researchers commonly investigate CJC 1295 with DAC in laboratory models focused on endocrine signaling, recovery-related biological activity, metabolic regulation, and peptide-driven growth hormone secretion mechanisms associated with long-acting receptor interaction dynamics.

CJC 1295 with DAC (5mg)

SKU cjc-1295-with-dac Category

CJC 1295 with DAC is a modified synthetic peptide engineered to stimulate growth hormone-releasing hormone receptors through prolonged biological activity and sustained peptide signaling pathways. The addition of Drug Affinity Complex (DAC) technology significantly extends the peptide’s half-life, making it widely researched in experimental models involving long-duration endocrine modulation and growth hormone secretion dynamics. Researchers investigate CJC 1295 with DAC for its role in peptide-mediated recovery pathways, metabolic activity, cellular repair signaling, and protein synthesis-related biological functions. Its long-acting structure is commonly explored in laboratory environments focused on hormonal rhythm regulation, tissue-support mechanisms, and extended receptor activation studies associated with growth hormone research. Due to its stability and prolonged activity profile, CJC 1295 with DAC remains a prominent compound in peptide-based scientific investigations involving endocrine communication and sustained biological signaling pathways. Each vial is supplied as research-grade lyophilized material with verified purity standards and controlled laboratory handling protocols.Molecular Formula: C₁₆₅H₂₆₉N₄₇O₄₆Molecular Weight: 3647.27 g/molStorage: Store lyophilized at −20°C under sterile laboratory conditionsFOR RESEARCH USE ONLY

Reviews

There are no reviews yet.

Be the first to review “CJC 1295 with DAC (5mg)”

Your email address will not be published. Required fields are marked *

COAS

PRODUCT BATCH TESTING ORDERED SAMPLE RECEIVED STATUS ACTION
BPC157 10mg 021 1 JULY 2025 7 JULY 2025 CURRENT View COA
IGF-1 LR3 1mg 020 2 APRIL 2026 13 APRIL 2026 CURRENT View COA
PT-141 021 2 FEB 2026 13 FEB 2026 CURRENT View COA
Retatrutide 20mg 020 2 MAY 2026 13 MAY 2026 CURRENT View COA
Semiglutide 10mg 020 2 MAY 2026 13 MAY 2026 CURRENT View COA
Semiglutide 30mg 020 2 MAY 2026 13 MAY 2026 CURRENT View COA
TB-500 021 2 FEB 2026 13 FEB 2026 CURRENT View COA
Tesamorelin 10mg 021 1 JULY 2025 7 JULY 2025 CURRENT View COA
Tirzepatide 30mg 020 2 MAY 2026 13 MAY 2026 CURRENT View COA
Scroll to Top